-
Infinity Pharmaceuticals NASDAQ:INFI Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings.
Location: 1100 Massachusetts Ave Ste 4, Massachusetts, 02138-5241, US | Website: www.infi.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
2.69%
Insider Ownership
2.36%
Institutional Own.
23.49%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Pembrolizumab Details Cancer, Head and neck squamous cell carcinoma, Solid tumor/s, Melanoma | Phase 2 Data readout | |
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Nivolumab Details Urothelial cancer, Cancer | Phase 2 Update | |
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + etrumadenant + Doxil® Details Breast cancer, Triple-negative breast cancer , Cancer | Phase 2 Update | |
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Nivolumab Details Solid tumor/s, Head and neck squamous cell carcinoma, Melanoma, Cancer | Phase 1b Data readout |